Bullseye or Tip of the Iceberg: Magnetic Resonance Imaging-visible Disease in Radiorecurrent Prostate Cancer

Affiliations

¹ Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California-Los Angeles, Los Angeles, CA, USA. Electronic address: aukishan@mednet.ucla.edu.
² Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA; Department of Radiation Oncology, Greater Los Angeles Veteran Affairs, Los Angeles, CA, USA.
³ Department of Urology, University of California-Los Angeles, Los Angeles, CA, USA.

Editorial

Amar U Kishan et al. Eur Urol. 2024 Jan.

. 2024 Jan;85(1):47-48.

doi: 10.1016/j.eururo.2023.09.018. Epub 2023 Oct 6.

¹ Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California-Los Angeles, Los Angeles, CA, USA. Electronic address: aukishan@mednet.ucla.edu.
² Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA; Department of Radiation Oncology, Greater Los Angeles Veteran Affairs, Los Angeles, CA, USA.
³ Department of Urology, University of California-Los Angeles, Los Angeles, CA, USA.

No abstract available

Comment on

The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
Light A, Kanthabalan A, Otieno M, Pavlou M, Omar R, Adeleke S, Giganti F, Brew-Graves C, Williams NR, Emara A, Haroon A, Latifoltojar A, Sidhu H, Freeman A, Orczyk C, Nikapota A, Dudderidge T, Hindley RG, Virdi J, Arya M, Payne H, Mitra AV, Bomanji J, Winkler M, Horan G, Moore CM, Emberton M, Punwani S, Ahmed HU, Shah TT. Light A, et al. Eur Urol. 2024 Jan;85(1):35-46. doi: 10.1016/j.eururo.2023.09.001. Epub 2023 Sep 29. Eur Urol. 2024. PMID: 37778954 Clinical Trial.